How Long Does Suboxone Stay in Your System?

Suboxone remains in the body far longer than most people expect with clearance time of approximately 5 to 8 days for most users at standard doses.

Its active ingredient buprenorphine carries an unusually long elimination half-life of 24 to 72 hours compared to most other opioid medications. Detection windows vary significantly by test type, and individual factors including liver function, dose history, and body composition can extend them meaningfully.

Understanding these timelines matters for drug screening, induction timing when switching medications, and clinical decisions about continuing or discontinuing treatment. The exact duration depends on which test is used, how long Suboxone was taken, and the dose.

Key Takeaways

• Buprenorphine, the active ingredient in Suboxone, carries a half-life of 24 to 72 hours, producing a total clearance time of approximately 5 to 8 days for most users at standard doses.
• Standard 5-panel urine drug tests do not screen for buprenorphine. A specific buprenorphine immunoassay or extended 10-panel test is required to detect Suboxone use.
• Norbuprenorphine, the primary active metabolite of buprenorphine, carries a half-life exceeding 150 hours and may remain detectable in urine for 14 or more days in long-term high-dose users.
• The Clinical Opiate Withdrawal Scale (COWS) is the validated instrument used to determine readiness for Suboxone induction; a score of 8 or higher generally indicates sufficient withdrawal for safe initiation.
• Transitioning from Suboxone to naltrexone (Vivitrol) requires a minimum 7-to-14-day washout period, with 30 days recommended to prevent precipitated withdrawal.

What Is Suboxone and How Does It Work?

Suboxone is a combination medication containing buprenorphine and naloxone in a 4:1 ratio, FDA-approved in 2002 for the treatment of opioid use disorder (OUD) as part of a medication-assisted treatment (MAT) program.

Buprenorphine: Partial Mu-Opioid Receptor Agonist

• Partial agonist mechanism: Buprenorphine binds to the mu-opioid receptor (MOR) with very high affinity but produces only partial activation. Unlike full agonists such as heroin or oxycodone, buprenorphine's activation of the MOR plateaus at higher doses due to a ceiling effect, reducing overdose risk significantly. Pioneer research by Donald Jasinski, MD, at NIDA in the 1970s first characterized buprenorphine's partial agonist pharmacological profile and established its low abuse potential relative to full agonists, forming the scientific foundation for FDA approval of Suboxone in 2002. This mechanism makes buprenorphine effective for suppressing heroin addiction cravings without reproducing full agonist euphoria.
• High receptor affinity and displacement: Buprenorphine's binding affinity for the MOR exceeds that of morphine, heroin, and oxycodone. This means buprenorphine physically displaces full agonists already occupying opioid receptors, which is why taking a full opioid agonist while buprenorphine occupies the receptor produces no effect and why starting buprenorphine too soon after a full agonist precipitates withdrawal.
• Additional receptor activity: Buprenorphine also acts as a kappa-opioid receptor antagonist and a partial agonist at the nociceptin/orphanin FQ receptor. These additional binding properties contribute to its antidepressant and antianxiety effects in some patients, supporting its therapeutic value in the context of the opioid epidemic.

Naloxone: The Abuse-Deterrent Component

• Full opioid antagonist added to deter injection: Naloxone is a full mu-opioid receptor antagonist that blocks and reverses opioid effects. It is included in Suboxone to deter misuse by injection. When Suboxone is used sublingually as prescribed, naloxone is poorly absorbed and produces minimal pharmacological effect. When injected, naloxone is fully absorbed and immediately precipitates acute opioid withdrawal in opioid-dependent individuals.
• Sublingual bioavailability difference: Buprenorphine has approximately 30–50% sublingual bioavailability, meaning a meaningful fraction crosses the oral mucosa and enters systemic circulation. Naloxone's sublingual bioavailability is below 10%, making it pharmacologically inactive at the sublingual route while remaining fully active if the film is dissolved and injected.
• Buprenorphine-only formulations: Subutex (sublingual tablets containing buprenorphine without naloxone) and Sublocade (extended-release injectable buprenorphine, administered monthly by a clinician) are available for patients where the naloxone component creates clinical complications, including pregnancy.

How the Body Metabolizes Suboxone

Suboxone's unusually long persistence in the body results from the specific pharmacokinetic properties of buprenorphine, including its high lipophilicity, extensive protein binding, and metabolic pathway through the CYP3A4 enzyme system.

CYP3A4 Hepatic Metabolism and Norbuprenorphine

• Primary hepatic metabolism via CYP3A4: Buprenorphine undergoes extensive first-pass metabolism in the liver primarily through the cytochrome P450 3A4 (CYP3A4) enzyme, with a minor contribution from CYP2C8. CYP3A4 N-dealkylates buprenorphine into norbuprenorphine, its primary active metabolite. Liver disease, which impairs CYP3A4 activity, significantly prolongs buprenorphine clearance.
• Norbuprenorphine: the long-lasting metabolite: Norbuprenorphine is itself pharmacologically active, binding the MOR with somewhat lower potency than buprenorphine. Its half-life exceeds 150 hours, substantially longer than buprenorphine's 24-to-72-hour half-life. Drug testing panels that detect buprenorphine typically also detect norbuprenorphine, and norbuprenorphine may remain positive in urine after buprenorphine itself has cleared.
• CYP3A4 drug interactions: Medications that inhibit CYP3A4, including clarithromycin, fluconazole, and ritonavir, slow buprenorphine metabolism and extend detection windows. Medications that induce CYP3A4, including rifampin, carbamazepine, and phenytoin, accelerate metabolism and shorten clearance. Clinicians prescribing medication-assisted treatment (MAT) must review all concurrent medications for CYP3A4 interactions before dose adjustment.

Why Suboxone Has an Unusually Long Half-Life

• High lipophilicity and tissue distribution: Buprenorphine is highly lipophilic, meaning it distributes extensively into fatty tissues throughout the body. Its volume of distribution ranges from approximately 188 to 335 liters, orders of magnitude larger than the body's total water volume. This extensive tissue sequestration means buprenorphine is slowly released back into plasma over days, extending the effective duration well beyond what blood concentration alone would suggest.
• High protein binding: Approximately 96% of circulating buprenorphine is bound to plasma proteins, primarily alpha- and beta-globulins. Only the unbound fraction is pharmacologically active and available for hepatic metabolism. High protein binding limits the rate of metabolic clearance and contributes to the long half-life.
• Enterohepatic recirculation: Buprenorphine glucuronide conjugates excreted in bile are hydrolyzed back to free buprenorphine in the intestinal tract and reabsorbed, creating an enterohepatic recirculation cycle that returns drug to systemic circulation and further extends the elimination timeline.

Suboxone Detection Windows by Drug Test Type

Detection time varies significantly by test type, dose, duration of use, and individual metabolic factors; the ranges below represent verified clinical reference windows for average therapeutic Suboxone doses.

Detection Time by Drug Test Type

Drug Test Type	Detection Window	Notes
Urine (immunoassay)	3–10 days; up to 14 days in long-term high-dose users	Requires specific buprenorphine panel; not detected on standard 5-panel SAMHSA test
Blood	1–3 days (buprenorphine); up to 5–7 days (norbuprenorphine)	Least common test type; used for acute clinical assessment or legal proceedings
Saliva	1–3 days	Reflects recent use most accurately; less subject to specimen adulteration than urine
Hair follicle	Up to 90 days (1.5 cm of hair per 30 days of drug use)	Reflects cumulative use over months; not useful for recent dose timing; most expensive test type

The Numbered Timeline: Suboxone Clearance After Last Dose

1. Hours 0–24: Buprenorphine is at or near peak plasma concentration. Blood tests, urine tests with specific buprenorphine panels, and saliva tests all return positive. The drug is pharmacologically active, blocking opioid receptors and suppressing withdrawal symptoms.
2. Hours 24–72 (Days 1–3): Buprenorphine levels fall as the first half-lives pass. Blood testing typically becomes negative within this window for most patients. Urine and saliva tests generally remain positive throughout this period.
3. Days 3–7: Saliva tests become negative for most users within this range. Urine tests using specific buprenorphine immunoassay panels continue to detect buprenorphine and/or norbuprenorphine in most standard therapeutic users. The drug is no longer pharmacologically active at blocking full agonists in most patients by Day 5–7.
4. Days 7–10: Most urine tests return negative for average-dose users at standard Suboxone doses. Individuals with hepatic impairment, high body fat percentage, or high doses may remain positive beyond Day 10.
5. Days 10–14: Norbuprenorphine metabolite may still produce a positive urine result in long-term high-dose users even after buprenorphine itself has cleared. A positive urine result in this window is typically driven by norbuprenorphine rather than buprenorphine.
6. Days 14–90: All standard urine and blood tests are negative for the vast majority of users. Hair follicle testing continues to detect prior Suboxone use throughout this window, providing historical evidence of drug use rather than current presence.

Factors That Affect How Long Suboxone Stays in Your System

Individual variation in Suboxone detection time is substantial; the following factors directly influence clearance rate and can extend or shorten the detection windows above.

Liver Function and CYP3A4 Activity

• Hepatic impairment significantly extends clearance: Liver disease reduces CYP3A4 enzyme activity, slowing buprenorphine metabolism. Patients with moderate or severe hepatic impairment may show buprenorphine half-lives two to three times longer than healthy controls, substantially extending urine detection windows. SCAT's clinical team assesses liver function through the history and physical conducted within the first 24 hours.
• CYP3A4 inhibitor medications: Concurrent use of azole antifungals (fluconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), or antiretrovirals (ritonavir) inhibits CYP3A4 and extends buprenorphine clearance. Patients on these medications may test positive for longer than the standard detection windows above indicate.
• CYP3A4 inducer medications: Rifampin, phenytoin, and carbamazepine accelerate CYP3A4 activity and shorten buprenorphine clearance. Patients taking inducers may require higher Suboxone doses to maintain therapeutic effect and may test negative earlier than standard windows predict.

Dose, Duration, and Formulation

• Dose magnitude: Higher single doses produce higher initial plasma concentrations, which take longer to clear through the half-life elimination process. A patient taking 24 mg per day takes meaningfully longer to test negative than one taking 4 mg per day, even when liver function and body composition are equivalent.
• Duration of use and tissue accumulation: Long-term Suboxone use produces drug accumulation in fatty tissues over weeks to months. At steady state, total body burden is substantially higher than what single-dose pharmacokinetics would predict. This accumulated tissue reservoir requires more clearance cycles, extending detection in long-term users relative to short-term users at the same dose.
• Extended-release formulations: Sublocade, the monthly subcutaneous injectable extended-release buprenorphine formulation, produces a depot that releases drug continuously. Following the last Sublocade injection, buprenorphine may remain detectable in urine for 30 or more days due to the sustained-release mechanism.

Body Composition and Metabolic Rate

• Body fat percentage: Buprenorphine's high lipophilicity means individuals with higher body fat accumulate more drug in fatty tissue compartments. Larger tissue reservoirs release drug slowly during clearance, extending detection windows compared to individuals with lower body fat percentages at equivalent doses.
• Basal metabolic rate: Higher metabolic rates generally increase hepatic enzyme activity and accelerate drug clearance. Factors reducing metabolic rate, including hypothyroidism, severe caloric restriction, and aging, can extend buprenorphine clearance.
• Urinary pH: Buprenorphine and norbuprenorphine are weak bases. Acidic urine enhances renal excretion of buprenorphine metabolites, potentially shortening detection. Alkaline urine reduces renal excretion and may extend detection. Normal dietary variation in urinary pH produces clinically meaningful day-to-day variation in urine test results near the detection threshold.

Suboxone and the COWS Scale: Timing Induction Correctly

Correctly timed Suboxone induction depends on an objective measurement of withdrawal severity rather than on elapsed hours since the last opioid dose; the Clinical Opiate Withdrawal Scale (COWS) is the validated instrument for this determination.

What the COWS Scale Measures

• COWS definition and scoring: The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered instrument measuring the objective and subjective signs of opioid withdrawal. Items include resting pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh, and runny nose or tearing. Total scores range from 0 to 47.
• Severity thresholds: A COWS score of 5–12 indicates mild withdrawal; 13–24 indicates moderate withdrawal; 25–36 indicates moderately severe withdrawal; 36 or above indicates severe withdrawal. A score of 8 or higher is generally considered sufficient withdrawal for safe Suboxone induction, though institutional protocols vary and individual clinical judgment applies.
• Why COWS scores matter for induction timing: Starting Suboxone when COWS score is below the induction threshold means full opioid agonists still occupy a significant proportion of mu-opioid receptors. Buprenorphine displaces them due to its higher binding affinity but produces only partial agonist activation, converting full agonist occupancy to partial agonist occupancy and precipitating acute withdrawal. Waiting for adequate receptor clearance, confirmed by COWS, prevents precipitated withdrawal.

The 3-Day Suboxone Rule and the 15-15-15 Guideline

• The 3-day Suboxone rule: This informal guideline reflects the observation that waiting approximately 72 hours after the last use of a short-acting full opioid agonist (such as heroin or oxycodone) provides sufficient time for most patients to develop a COWS score high enough to safely initiate buprenorphine. The rule is not a fixed clinical protocol; the actual determinant of induction readiness is the COWS score, not the elapsed time. For long-acting opioids like methadone, 72 hours is typically insufficient and 4–7 days or longer may be required.
• Fentanyl and extended induction delays: Illicit fentanyl's variable half-life and tissue accumulation from chronic use means standard induction protocols frequently produce precipitated withdrawal even after 72 or more hours. Low-dose buprenorphine induction protocols (starting at 0.5–2 mg and titrating slowly) are increasingly used for fentanyl-dependent patients to minimize precipitated withdrawal risk regardless of the time elapsed since last use.
• The 15-15-15 guideline: The 15-15-15 rule is an informal patient-community guideline, not a validated clinical protocol. It is sometimes described as waiting 15 hours since the last opioid use, achieving a COWS score of 15, with the last dose being 15 mg morphine equivalent or less. Because this guideline is not derived from randomized controlled trial data and does not account for fentanyl or long-acting opioid pharmacokinetics, patients should follow individualized clinical guidance from their prescribing provider rather than applying this rule independently.

Suboxone vs. Methadone vs. Naltrexone: MAT Options Compared

All three FDA-approved medications for opioid use disorder have distinct pharmacological profiles, delivery requirements, and clinical indications that directly affect detection times and treatment planning.

Feature	Suboxone (Buprenorphine/Naloxone)	Methadone	Naltrexone (Vivitrol)
Opioid receptor action	Partial mu-opioid agonist + kappa antagonist	Full mu-opioid agonist	Full mu-opioid antagonist (no agonist effect)
Half-life	24–72 hours (buprenorphine)	24–72 hours (more variable; QTc risk)	5–10 days (extended-release injection)
Urine detection window	3–10 days (specific panel required)	3–7 days (standard opiate panel)	Not detected on standard drug tests
Dispensing setting	Office-based, monthly prescription possible	Daily dispensing at licensed OTP clinic initially	Monthly injection at clinic or prescriber office
Detox required first	No (replaces opioid with partial agonist)	No (replaces opioid with full agonist)	Yes (complete detox required; 7–14+ days opioid-free)
Overdose risk	Low (ceiling effect limits respiratory depression)	Higher (no ceiling effect; QTc prolongation)	None from naltrexone itself; opioid sensitivity increased post-blockade
Best candidate	Motivated patients preferring office-based treatment	Patients needing structured daily accountability	Fully detoxed patients with strong motivation and social support

Treatment for Opioid Use Disorder at SC Addiction Treatment

SC Addiction Treatment (SCAT) in Simpsonville, South Carolina, provides CARF-accredited, medically supervised detox and residential care for adults with opioid use disorder, including those currently on buprenorphine-based MAT who require medically managed withdrawal or residential stabilization.

Medically Supervised Opioid Detox

• Comprehensive assessment within 24 hours: All clients complete the Big Four assessments (nursing assessment, biopsychosocial assessment, history and physical, and psychiatric evaluation) within 24 hours of admission. The history and physical, conducted by SCAT's licensed clinical staff under the oversight of Medical Director Dr. Dimitrova (MD, psychiatrist), includes medication review for CYP3A4 interactions, hepatic function indicators, and current MAT status to inform detox protocol selection.
• COWS-guided clinical monitoring: SCAT's licensed nursing staff assess withdrawal severity throughout Track One using validated instruments including the COWS Scale. Clinical management during opioid detox is individualized to each client's withdrawal trajectory. The 16-bed maximum census and 24-hour licensed staff coverage ensure that COWS-triggered intervention occurs promptly when withdrawal severity escalates.
• Medically supervised withdrawal management: For clients managing opioid use disorder, SCAT's medical team provides protocol-based withdrawal management throughout the 7-day Track One detox period. The detox protocol is adapted to each client's substance use history, current opioid addiction treatment needs, and co-occurring medical or psychiatric conditions identified during the Big Four assessment process.

MAT Aftercare and Referrals

• MAT clinic connections in aftercare planning: SCAT's clinical case manager coordinates MAT clinic referrals as a core component of aftercare planning for clients with opioid use disorder. Aftercare options include connections to prescription drug addiction specialists, MAT providers, and individual counselors who can continue buprenorphine prescribing and monitoring in the outpatient setting post-discharge.
• Transportation up to 2.5 hours for continued care: SCAT provides transportation assistance up to 2.5 hours from the Simpsonville, South Carolina facility to connect clients with preferred partner facilities for PHP, IOP, and MAT services. This continuity removes one of the most common barriers to sustained engagement with MAT following an acute detox admission.
• SCAR alumni program: Clients discharged from SCAT are eligible for the SCAR (Soar) alumni program, a monthly community meeting in the Greenville area that provides ongoing peer support, recovery resources, and community connection to reduce relapse risk during the highest-vulnerability period following residential discharge.

For information about addiction treatment programs or to begin the admissions process, contact the admissions team at SC Addiction Treatment directly.

"One of the most common questions we hear from clients and families is how long Suboxone will show up on a drug test. The honest answer is that it depends on the test type, the dose, and the individual's liver function. Standard 5-panel drug tests don't detect buprenorphine at all, but specialized panels used by many employers and courts do. Knowing the specific test you're facing is the first step toward understanding your timeline."

Sahil Talwar, PA-C, MBA, Medical Reviewer, SC Addiction Treatment

Frequently Asked Questions

What is the washout period for Suboxone?

The washout period for Suboxone depends on the clinical context. For most purposes, buprenorphine is considered cleared after 5 to 8 days from the last dose at standard therapeutic doses. For transitioning to naltrexone (Vivitrol), a minimum 7-to-14-day opioid-free period is required, with 30 days recommended to fully prevent precipitated withdrawal when buprenorphine's tissue-bound reserves release slowly over time.

What is the 3-day Suboxone rule?

The 3-day Suboxone rule is an informal guideline suggesting that waiting approximately 72 hours after the last short-acting full opioid use typically produces sufficient withdrawal (COWS score of 8 or higher) to safely begin Suboxone induction. It is not a fixed clinical protocol. For long-acting opioids like methadone or illicit fentanyl, 72 hours is frequently insufficient, and longer waiting periods or low-dose induction protocols are required. The COWS score, not elapsed time, is the definitive indicator of induction readiness.

What is the 15-15-15 rule for Suboxone?

The 15-15-15 rule is an informal patient-community guideline, not a validated clinical protocol. It is described as waiting 15 hours since the last opioid use, having a COWS score of at least 15, with the last opioid dose being 15 mg morphine equivalent or less. This guideline is not derived from clinical trial data and does not account for fentanyl pharmacokinetics or individual variation in clearance.

Patients should always follow individualized induction guidance from a qualified prescriber rather than applying this rule independently.

How long does Suboxone stay in urine?

Suboxone is detectable in urine for 3 to 10 days for most users at standard therapeutic doses on a specific buprenorphine immunoassay panel. Long-term high-dose users may test positive for up to 14 days due to tissue-accumulated buprenorphine and the extended half-life of norbuprenorphine, the primary active metabolite. Standard 5-panel urine drug tests used by many employers and courts do not screen for buprenorphine at all and will return negative regardless of Suboxone use.

Does Suboxone show up on a standard drug test?

No. The standard SAMHSA 5-panel urine drug test screens for amphetamines, cocaine, marijuana, opiates (specifically morphine and codeine), and PCP. Buprenorphine is not included on the standard 5-panel test and will not produce a positive result. Detecting Suboxone requires a specific buprenorphine immunoassay, a 10-panel extended test that includes buprenorphine, or a comprehensive confirmatory test such as GC-MS or LC-MS/MS ordered specifically for buprenorphine.

Knowing how long other substances stay in your system requires the same test-specific inquiry.

How long does Suboxone block opioids?

Suboxone's opioid-blocking effect persists for roughly 24 to 72 hours after a single dose at therapeutic levels, corresponding to its elimination half-life. During this window, buprenorphine occupies the mu-opioid receptor with high enough affinity to competitively block full agonist opioids from producing their effects. At standard maintenance doses of 8 to 24 mg per day, receptor occupancy remains sufficient throughout the dosing interval to block both cravings and the reinforcing effects of illicit opioids.

Can I speed up how fast Suboxone leaves my system?

There is no proven clinical intervention that meaningfully accelerates buprenorphine clearance. Adequate hydration supports normal renal excretion of metabolites but does not substantially shorten detection windows. Avoiding CYP3A4 inhibitor medications removes a factor that extends clearance. Physical activity may modestly increase metabolic rate, but the primary determinant of clearance time is buprenorphine's pharmacokinetic profile, not behavioral factors.

Patients should avoid any approach marketed as "flushing" the drug, as these methods are clinically unsupported and may carry health risks.

What happens if you take opioids while on Suboxone?

Taking a full opioid agonist while buprenorphine occupies the mu-opioid receptor typically produces no euphoric effect, because buprenorphine's higher binding affinity and partial agonist ceiling prevent full agonist activation. However, taking large doses of a powerful opioid like illicit fentanyl while on Suboxone can still produce respiratory depression and overdose risk, because fentanyl's potency can partially overcome buprenorphine's blocking effect.

Adding other central nervous system depressants such as benzodiazepines alongside opioids increases overdose risk substantially, as documented in benzodiazepine dependence literature.

References

1. Substance Abuse and Mental Health Services Administration. (2021). TIP 63: Medications for Opioid Use Disorder. U.S. Department of Health and Human Services. https://store.samhsa.gov
2. Food and Drug Administration. (2002). Suboxone (buprenorphine and naloxone) sublingual film prescribing information. U.S. Department of Health and Human Services.
3. Jasinski, D. R., Pevnick, J. S., & Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry, 35(4), 501–516.
4. Elkader, A., & Sproule, B. (2005). Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics, 44(7), 661–680.
5. Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259.
6. Moody, D. E., Fang, W. B., Morrison, J., & McCance-Katz, E. (2011). Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug and Alcohol Dependence, 118(2–3), 479–483.
7. National Institute on Drug Abuse. (2023). Buprenorphine. U.S. Department of Health and Human Services. https://nida.nih.gov
8. Substance Abuse and Mental Health Services Administration. (2024). Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.
9. Lintzeris, N., & Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. The American Journal on Addictions, 19(1), 59–72.